Inovio Pharmaceuticals Stock News

Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

These two companies have been left in the dust. Is it too late for them?

Primary and secondary endpoints met in late-stage REVEAL 1 which used VGX-3100 for women with HSIL. Results form the second late-stage study REVEAL 2, using VGX-3100 for women with HSIL, expected in Q

Some cheap stocks aren't bargains.

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)

This vaccine laggard suffered a new setback -- but there is one piece of good news.

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

The company's Q4 results didn't provide a lot of fuel for optimism.

The company's Q4 results didn't provide a lot of fuel for optimism.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome

Inovio Pharmaceuticals (INO) is pausing enrollment in a phase 3 trial of its COVID-19 vaccine INO-4800 to amend the main goal of the study after the shot showed significantly…

INO earnings call for the period ending December 31, 2021.

INO earnings call for the period ending December 31, 2021.